Sglt 2i CKD Farxiga denied as non-formulary by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Placed Farxiga Off-Formulary for CKD — and How to Appeal

A non-formulary denial means dapagliflozin (Farxiga) is not listed on Cigna's preferred drug list for your plan, or is placed at a tier that requires additional authorization or results in a benefit that does not cover it. For CKD, this is particularly important to challenge because dapagliflozin has a specific FDA-approved CKD indication that not all SGLT2 inhibitors share — so a straightforward "use a formulary alternative" response from Cigna may not be clinically acceptable.

Non-formulary denials are appealed through the plan's formulary exception or medical-necessity exception process, which is separate from — but closely linked to — the standard appeal process.

### Why a Formulary Exception Is Frequently Granted

Plans are required under the ACA and many state laws to grant formulary exceptions when (a) every formulary alternative is contraindicated for or has been tried and failed in the patient, or (b) no formulary alternative is FDA-approved for the patient's specific indication. If Cigna's formulary alternative does not carry the same FDA-approved CKD indication as dapagliflozin, your prescriber has a strong basis for a formulary exception request.

### Federal Appeal Framework

• Formulary exception request: File with your prescriber's medical-necessity supporting documentation. Cigna must respond within the standard urgent (expedited) or non-urgent timeline.
• Internal appeal (ACA / ERISA §503): If the exception is denied, file a formal internal appeal within the deadline shown on the denial letter.
• External review (ACA §2719): A final adverse internal decision entitles you to independent external review, typically within four months of the final denial. The decision is binding.
• Expedited option: Request expedited review if delay would seriously jeopardize health.

### Concrete Appeal Steps and Timeline

1. Identify which drug Cigna designates as the formulary alternative for your CKD indication. 2. Pull the FDA prescribing label for that alternative and compare the approved indications to Farxiga's CKD indication. 3. If the alternative lacks the same CKD indication, document this in writing and attach both labels. 4. If the alternative was previously tried and failed, compile dated records of that trial. 5. Ask your prescriber to write a formulary-exception letter documenting: the FDA-approved CKD indication for dapagliflozin, the deficiency of the formulary alternative for this specific indication, and the patient's clinical need. 6. File the formulary exception and simultaneously begin the internal appeal paperwork in case the exception is denied.

### Documentation to Gather

• FDA prescribing labels: Both Farxiga and the formulary alternative, with indications sections highlighted for comparison.
• CKD diagnosis and staging records: Chart notes confirming the diagnosis and clinical course.
• Prior-drug trial records: If the formulary alternative was tried, dated chart notes and pharmacy records documenting the trial and outcome.
• Prescriber letter: A signed letter addressing formulary-exception criteria under Cigna's policy and the clinical reasons dapagliflozin is medically necessary.

### Criteria-Mapping Structure

For each criterion in Cigna's formulary exception policy, provide a written response paired with the specific supporting document. The most powerful argument is an FDA-label comparison showing indication-level differences between dapagliflozin and the proposed formulary substitute. Present that comparison clearly and early in the appeal.